Pharmacokinetics and ex vivo anti‐inflammatory effects of oral misoprostol in horses
Open Access
- 26 September 2018
- journal article
- research article
- Published by Wiley in Equine Veterinary Journal
- Vol. 51 (3) , 415-421
Abstract
Summary: Background: Misoprostol is an E prostanoid (EP) 2, 3 and 4 receptor agonist that is anecdotally used to treat and preventNSAID‐inducedGIinjury in horses. Misoprostol elicits anti‐inflammatory effects in vivo in men and rodents, and inhibitsTNFα production in equine leucocytes in vitro.Objective: Define the pharmacokinetic parameters of oral misoprostol in horses, and determine the inhibitory effect of oral misoprostol administration on equine leucocyteTNFα production in an ex vivo inflammation model.Study design: Pharmacokinetic study, ex vivo experimental study.Methods: Six healthy adult horses of mixed breeds were used. In phase one, horses were given 5 μg/kg misoprostol orally, and blood was collected at predetermined times for determination of misoprostol free acid (MFA) byUHPLC‐MS/MS. Pharmacokinetic parameters were calculated. In phase two, horses were dosed as in phase one, and blood was collected at T0, 0.5, 1 and 4 h following misoprostol administration for leucocyte isolation. Leucocytes were stimulated with 100 ng/mLLPS, andTNFαmRNAconcentrations were determined via quantitative real‐time PCR.Results: About 5 μg/kg oral misoprostol produced a rapid time to maximum concentration (Tmax) of 23.4 ± 2.4 min, with a maximum concentration (Cmax) of 0.29 ± 0.07 ng/mL and area under the curve (AUC0−∞) of 0.4 ± 0.12 h ng/mL.LPSstimulation of equine leucocytes ex vivo significantly increasedTNFαmRNAconcentrations, and there was no significant effect of misoprostol even at the Tmax.Main limitations: Only a single dose was used, and sample size was small.Conclusions: Misoprostol is rapidly absorbed following oral administration in horses, and a single 5 μg/kg dose had no significant inhibitory effect on ex vivoLPS‐stimulatedTNFαmRNAproduction in leucocytes. Further studies analysing different dosing strategies, including repeat administration or combination with other anti‐inflammatory drugs, are warranted.Keywords
Funding Information
- Morris Animal Foundation (D15EQ018)
This publication has 49 references indexed in Scilit:
- Mid‐gestation pregnancy is not disrupted by a 5‐day gastrointestinal mucosal cytoprotectant oral regimen of misoprostolEquine Veterinary Journal, 2012
- The effect of nonsteroidal anti‐inflammatory drugs on the equine intestineEquine Veterinary Journal, 2011
- CXCL8 attenuates chemoattractant-induced equine neutrophil migrationVeterinary Immunology and Immunopathology, 2011
- Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemiaNeuroscience Letters, 2008
- Misoprostol: Pharmacokinetic profiles, effects on the uterus and side‐effectsInternational Journal of Gynecology & Obstetrics, 2007
- Effects of stimulation of adenosine A2A receptors on lipopolysaccharide-induced production of reactive oxygen species by equine neutrophilsAmerican Journal of Veterinary Research, 2007
- The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurementsNature Biotechnology, 2006
- Evaluation of DNA microarray results with quantitative gene expression platformsNature Biotechnology, 2006
- MISOPROSTOL STIMULATES cAMP GENERATION IN HUMAN LEUKOCYTESAmerican Journal of Therapeutics, 1995
- The effect of prostaglandin E1 on motility of the equine gutJournal of Veterinary Pharmacology and Therapeutics, 1985